Aims: To explore the treatment outcomes in adult patients with type 2 diabetes (T2D) enrolled in the GetGoal trials of lixisenatide (LIXI), and the predictive effects of baseline characteristics on outcomes.
weight, insulin secretion and sensitivity, and potential for hypoglycaemia. 1 Current recommendations for the choice of initial and add-on therapies are therefore based on individual baseline patient characteristics, such as glycaemic profile, weight and comorbidities. [1] [2] [3] [4] Lixisenatide (LIXI) is a once-daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of people with T2D that was recently approved by the US Food and Drug Administration and is also approved for use in several other countries. The GetGoal trial programme is a series of international, multicentre, phase III clinical trials assessing the efficacy and safety of LIXI in adult patients with T2D on a range of background therapies. Data from these trials showed that LIXI as monotherapy or add-on therapy to OADs or basal insulin significantly improved HbA1c levels and was associated with pronounced PPG reductions, a low rate of hypoglycaemia, and beneficial effects on weight. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Ideally, it would be valuable to identify those patients who would most benefit from specific therapies, allowing more targeted treatment approaches. Identifying patient characteristics that are predictive of poorer outcomes may also allow clinicians to identify patients who may benefit from alternative approaches to meet their treatment goals, or additional support, in order to attain their goals. The objective of the present study was to explore the effects of baseline characteristics on end-of-treatment outcomes in patients with T2D initiating LIXI in the GetGoal trials.
| MATERIALS AND METHODS

| Study design
This was a pooled analysis of patient-level data from LIXI GetGoal studies conducted by Sanofi. The GetGoal studies were phase III, prospective, randomized controlled trials of LIXI in adult patients with T2D. The studies included in the present analysis were the 24-week, placebo-controlled 
| Efficacy and safety endpoints
Efficacy and safety endpoints included change from baseline in HbA1c, FPG and PPG levels, PPG excursion, patients achieving HbA1c <7.0% (53 mmol/mol), incidence of severe hypoglycaemia and symptomatic hypoglycaemia, and weight change. Severe hypoglycaemia was defined as a hypoglycaemic event requiring assistance.
Symptomatic hypoglycaemia was defined as confirmed blood glucose <3.33 mmol/L (60 mg/dL) or hypoglycaemia with prompt recovery after oral carbohydrate administration. The following composite endpoints were also evaluated: endpoint HbA1c levels <7.0% (53 mmol/ mol) with no weight gain (no weight gain was defined as change in weight [endpoint -baseline weight] ≤ 0); endpoint HbA1c levels <7.0% (53 mmol/mol) with no symptomatic hypoglycaemia; endpoint HbA1c levels <7.0% (53 mmol/mol) with no weight gain and no symptomatic hypoglycaemia.
| Statistical analysis
In these analyses, two distinct questions were addressed. Firstly, the effects of LIXI or placebo treatment and the impact of baseline ther- 3 | RESULTS
| Patient baseline characteristics
Overall, pooled data for 2760 patients on baseline OAD therapy and 1198 on baseline basal insulin therapy were included in the analysis.
There were no significant differences in mean baseline age, BMI, known duration of diabetes, and HbA1c levels between treatment groups (LIXI and placebo) in each of the study arms ( 
| Effect of treatment on outcomes
Results were generally consistent between the OAD and basal insulin baseline therapy groups. Compared with placebo, LIXI was associated with significantly improved glycaemic outcomes in patients receiving either OADs or basal insulin. Decreases in HbA1c, PPG, PPG excursion, weight and BMI from baseline were significantly greater in the LIXI group compared with the placebo group in patients receiving
OADs and those receiving basal insulin (Table 2 ). Decreases in FPG were significantly greater in the LIXI group compared with placebo in patients receiving OADs, but the difference was not significant for those in the basal insulin group ( Table 2) .
The proportion of patients experiencing ≥1 symptomatic hypoglycaemic event was significantly higher with LIXI vs placebo in patients treated with OADs or basal insulin ( Table 2 ). The incidence of severe hypoglycaemia was low in all groups. In all, 1 patient (0.05%) in the OAD and LIXI group and 5 patients (0.75%) in the basal insulin and LIXI group experienced ≥1 severe hypoglycaemic event compared with no patients in any placebo group (P value not significant for comparison between treatment groups).
Significantly more patients treated with LIXI met composite endpoints of HbA1c <7.0% (53 mmol/mol) with no weight gain and no symptomatic hypoglycaemia compared with placebo (Table 2 ). This was highly significant (P < .0001), both when LIXI was added to basal insulin and to OADs.
| Predictors of outcomes
The change in HbA1c with LIXI or placebo was stratified by selected baseline characteristics in both the OAD ( Regression analysis identified LIXI treatment and baseline HbA1c as strong predictors of a range of clinical endpoints (Table 3 ). Other baseline characteristics were generally weaker and variable predictors of outcomes (Table 3) . LIXI treatment was a strong predictor of HbA1c change, PPG change, weight change, symptomatic hypoglycaemia and achievement of HbA1c <7.0% (53 mmol/mol) in both the OAD and basal insulin therapy groups (Table 3) , and a greater likelihood of achieving composite endpoints of HbA1c <7.0% (53 mmol/mol) without weight gain and/or symptomatic hypoglycaemia compared with placebo (Table 3 ). Higher baseline
HbA1c predicted a greater reduction in HbA1c in both the OAD and basal insulin groups (P < .0001 for both; Table 3) . Lower baseline HbA1c level was, however, a predictor of achieving HbA1c <7.0% (53 mmol/ symptomatic hypoglycaemia and no weight gain) in both the OAD and basal insulin baseline therapy groups (P < .0001 for all; Table 3 ).
Baseline HbA1c level was also a predictor of other clinical outcomes including FPG change, PPG change, weight change and composite endpoints, but was not a significant predictor of symptomatic hypoglycaemia for either treatment group (P = .2196 and P = .5434
for the OAD and basal insulin groups, respectively). Baseline BMI, baseline FPG level, baseline PPG level, baseline PPG excursion, age, sex and known duration of diabetes were predictive for some endpoints, but this varied between the OAD and basal insulin groups and tended to be small effects that were not clinically relevant (Table 3 ).
In additional regression analyses, age, sex and baseline BMI did not show a significant interaction with LIXI or placebo treatment (P > .05 for all in both the OAD and basal insulin baseline therapy groups). LIXI treatment was also shown to be a predictor of symptomatic hypoglycaemia when added to either OADs or basal insulin.
Several studies of patients treated with GLP-1 RAs have investigated the predictive effects of baseline factors on outcomes. As in the present study, most of these studies indicated a significant correlation between baseline HbA1c and change in HbA1c, so that patients with higher baseline HbA1c levels had greater decreases in HbA1c. [15] [16] [17] [18] [19] [20] Lower baseline HbA1c has been shown to be associated with greater target HbA1c achievement, 16 as was also shown in the present analysis.
The reported predictive value of other variables for outcomes in patients treated with GLP-1 RAs has been less consistent. For example, baseline weight was shown to be a determinant of HbA1c reduction in a study by Lapolla et al., 18 but baseline weight and BMI were shown not to be predictive in other studies. 15, 17, 19, 20 In the present study, baseline BMI had a minor, but significant, predictive value for HbA1c reduction in the basal insulin but not the OAD group; however, LIXI led to a significantly greater reduction in HbA1c than placebo irrespective of baseline BMI. Some studies have shown a correlation between weight change and baseline BMI 15 or baseline weight. 18 In the present study, baseline BMI was not predictive of weight change in patients treated with basal insulin, but had a small predictive value for weight change in the OAD group (treatment estimate 0.07 kg per 1 kg/m 2 increase in BMI; P < .0001). A recent analysis showed that treatment with a GLP-1 RA improved glycaemic parameters independently of weight change. 21 Although the degree HbA1c change from baseline in the LIXI and placebo treatment groups, stratified by A, baseline HbA1c; B, age; C, baseline BMI; D, known duration of diabetes; E, sex and F, baseline PPG, in the GetGoal trials with baseline OAD therapy. *P < .05; **P < .01; ***P < .001 for placebo vs LIXI treatment. Error bars indicate standard errors.
of improvement increased with increased weight loss, reductions in median HbA1c and FPG were seen across all weight loss quartiles, including the quartile with modest weight gain; however, the correlation between change in weight and change in HbA1c was found to be weak overall. 21 Because one of the mechanisms of action of GLP-1 RAs is increased insulin secretion, it has been postulated that the decline in β-cell function seen over time in diabetes may act to limit the action of GLP-1 RA. In our pooled analysis there was no evidence of smaller changes in HbA1c with longer known duration of diabetes, and this result is supported by many 15, 17, 19 but not all 18 other studies of GLP-1 RAs in T2D. The lack of association between disease duration and response to GLP-1 RAs may be attributable to improvements in β-cell function, shown in human studies using markers of function such as homeostasis model assessment (HOMA) score, [22] [23] [24] or relate to protection of β-cell mass after treatment with GLP-1 RAs, which has been shown in animals. 25, 26 The study that showed a relationship between disease duration and diminished GLP-1 RA response proposed that this may have been related to higher failure in β-cell function as a result of previous long-duration sulphonylurea use. 18 Evidence suggests that the PPG reduction with LIXI is driven by slowed gastric emptying and reduced postprandial insulin secretion, 27, 28 which may also explain why the efficacy of LIXI may be independent of the duration of diabetes. However, as there were no direct HbA1c change from baseline in the LIXI and placebo treatment groups, stratified by A, baseline HbA1c; B, age; C, baseline BMI; D, known duration of diabetes; E, sex and F, baseline PPG, in the GetGoal trials with baseline basal insulin therapy. *P < .05; **P < .01; ***P < .001 for placebo vs LIXI treatment. Error bars indicate standard errors. For comparisons of categorical variables, the first listed variable is the reference.
Values set in bold represent significant P values of < .05.
Only data for significant predictors are shown. Predictors evaluated were: LIXI vs placebo; baseline HbA1c (per 1%); age (per year); baseline BMI (per 1 kg/m 2 ); duration of diabetes (per year); female vs male; baseline FPG; baseline PPG; and baseline PPG excursion.
1 Measured by standardized meal test.
2 2-h PPG levels minus plasma glucose levels 30 minutes before the standardized meal test.
